title: [Thrombotic risk in myeloproliferative neoplasms: what the general practitioner needs to know].
abstract: Polycythaemia vera, essential thrombocythemia and primary myelofibrosis are stem cell-derived clonal haemopathies classified in the group of myeloproliferative neoplasms. Their clinical course may be complicated by both arterial and venous (sometimes in unusual sites) thrombotic events. Although general risk factors contribute to the prevalence of thrombotic events in this population, some other risk factors are specifically associated with the myeloproliferative neoplasms. The treatment options are aspirin, anticoagulation, cytoreduction and phlebotomies.
authors.affiliation: Service d'angiologie et d'hémostase HUG et Faculté de médecine de Geneve, 1211 Geneve 14. alessandro.casini@hcuge.ch
authors.forename: A
authors.initials: A
authors.lastname: Casini
authors.forename: F
authors.initials: F
authors.lastname: Boehlen
authors.forename: T
authors.initials: T
authors.lastname: Lecompte
authors.forename: P
authors.initials: P
authors.lastname: de Moerloose
mesh_terms: D019046:Bone Marrow Neoplasms / Q000150:complications*; D058006:General Practice; D006801:Humans; D009196:Myeloproliferative Disorders / Q000150:complications*; D012307:Risk Factors; D013927:Thrombosis / Q000453:epidemiology / Q000209:etiology*